Contractor
AURAVAX THERAPEUTICS, INC.
HOUSTON, TX
- UEI
- PAN3ZK2YLAL2
- Resolved by
- uei
- Confidence
- 1.000
Obligated to date
$749,9991
Awards
1
Agencies served
1
Active from Sep 16, 2024 to Sep 30, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75A50124C00054 THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN | Department of Health and Human Services | TX | Sep 16, 2024 | $749,999 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier PAN3ZK2YLAL2, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Oct 21, 2026.